This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SOCS3 / Suppressor of cytokine signaling 3 · IHC design guide
Design Immunohistochemistry for SOCS3
Plan SOCS3 chromogenic IHC in paraffin sections using its predominantly cytoplasmic tissue pattern (HPA tissue IHC). Compare high staining in fallopian tube non-ciliated cells and gallbladder glandular cells with cell populations reported as undetected (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SOCS3 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Staining pattern | Mostly cytoplasmic; high in fallopian tube non-ciliated cells (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet PA1707) | |
| Positive control | Fallopian tube+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | Adipocytes are undetected despite adipose RNA enrichment (HPA tissue IHC; HPA RNA) | |
| Regulation | Cytokine inducible (UniProt) | |
| Isoform / epitope | No annotated isoforms; one chain, residues 1–225 (UniProt) |
Section 1
Recommended SOCS3 IHC & IF Protocols
The catalog antibody uses citrate pH 6 retrieval (datasheet PA1707). The published protocols below cover human tissues and rat lung (PMC3070874; PMC7474768; PMC3445460).
| Sample | Paraffin-embedded human tonsil tissues; fixative not specified (datasheet PA1707) |
| Fixation | Image fixative and duration unreported (datasheet PA1707); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet PA1707) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet PA1707) |
| Primary antibody | Rabbit anti-SOCS3, 0.5-1μg/ml (datasheet PA1707) |
| Primary incubation | Overnight at 4 °C (datasheet PA1707) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet PA1707) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SOCS3-positive staining in non-ciliated cells of fallopian tube (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6 heat retrieval for the catalog antibody (datasheet PA1707); a human tissue study used high-pH heat retrieval (PMC3070874).
Section 2
What Is the Expected SOCS3 Staining Pattern?
SOCS3 staining in paraffin tissue sections should be predominantly cytoplasmic in the cells that express it (HPA tissue IHC: cytoplasmic expression in most tissues). Expect strong staining in fallopian tube non-ciliated cells and gallbladder glandular cells (HPA tissue IHC: High in both). SOCS3 has no transmembrane segment (UniProt O14543 topology). HPA rates its tissue pattern Approved, pending external verification (HPA tissue IHC reliability).
| Strong cytoplasmic staining in fallopian tube non-ciliated cells or gallbladder glandular cells. | This matches the cell types and High staining levels reported for those tissues (HPA tissue IHC). Judge the signal in the named cells; an entire tissue section need not stain uniformly (general IHC practice). |
| Predominantly nuclear staining, with little cytoplasmic signal in the expected cells. | Treat this as a localization mismatch: HPA describes tissue staining as cytoplasmic and ICC-IF localization as mainly cytosolic (HPA tissue IHC; HPA subcellular). Check controls before assigning a biological explanation (general IHC practice). |
| Prominent staining in adipocytes, prostate glandular cells or lymph-node germinal-center cells. | HPA reports these cell types as Not detected (HPA tissue IHC). Cross-reactivity or endogenous detection activity are possibilities, not diagnoses; compare the cell type and negative controls before interpreting the stain (general IHC practice). |
| Color spread across the section without clear cell borders or a repeatable cytoplasmic pattern. | Diffuse background cannot establish SOCS3-positive cells. Compare a no-primary control and review blocking, washing and chromogen development (general IHC practice); HPA's tissue pattern is cellular and cytoplasmic (HPA tissue IHC). |
| No staining in the expected cells of a fallopian tube or gallbladder section. | The result conflicts with HPA's High observations for the specified cells (HPA tissue IHC), but absence in one run does not establish biological absence. Confirm that those cells are present and assess the run's controls and detection steps (general IHC practice). |
💡Expected SOCS3 appearanceA convincing positive shows strong, cell-associated cytoplasmic staining in fallopian tube non-ciliated or gallbladder glandular cells (HPA tissue IHC: High); isolated nuclear color or diffuse section-wide color warrants control-based review (HPA tissue IHC; general IHC practice).
| Cell type and tissue selection | HPA reports Medium staining in bone-marrow hematopoietic cells, bronchial basal cells, cortical neurons and colon glandular cells, but Not detected in several other named cell types (HPA tissue IHC). Select and score the reported cells, not the tissue name alone (general IHC practice). |
| Protein staining versus RNA | Adipose tissue is RNA tissue-enhanced, while adipocytes are Not detected by tissue IHC (HPA tissue IHC). The RNA designation therefore cannot substitute for a protein-staining positive control in adipocytes (HPA tissue IHC). |
| Localization and molecular features | SOCS3 has no annotated subcellular location, signal peptide or transmembrane segment in this UniProt record (UniProt O14543). HPA tissue IHC supplies the cytoplasmic expectation; these sequence features alone do not establish a membrane or nuclear tissue pattern (UniProt O14543; HPA tissue IHC). |
| IF/ICC Q: Does membrane signal change the IHC expectation? | A: HPA ICC-IF reports mainly cytosolic localization with additional plasma-membrane localization (HPA subcellular). That observation does not replace HPA's predominantly cytoplasmic tissue IHC pattern or validate membrane-only staining in a paraffin section (HPA tissue IHC; HPA subcellular). |
| Strength of antibody evidence | HPA lists CAB012220 as IHC Approved and HPA068569 as ICC Approved; these are separate application ratings (HPA antibodies). The tissue profile is also Approved but pending external verification (HPA tissue IHC reliability). Neither statement establishes an Enhanced IHC validation rating (HPA antibodies). |
| Situation | Likely cause | Next action |
|---|---|---|
| The expected positive cells are unstained, and controls also fail. | A run-level problem in staining or detection is possible (general IHC practice); HPA reports High staining in the named fallopian tube and gallbladder cells (HPA tissue IHC). | Confirm those cells are present, then review antibody use, retrieval, reagent order and detection controls for this run (general IHC practice). Do not infer SOCS3-specific retrieval or fixation sensitivity from HPA's staining level. |
| Expected cells stain weakly, but the run controls work. | Cell selection or scoring may account for the apparent discrepancy (general IHC practice); HPA levels refer to specified cells, and other listed cells have Medium or Low levels (HPA tissue IHC). | Recheck the annotated cell population and compare like-for-like regions. Record the observed compartment and intensity separately (general IHC practice), using HPA's cell-level pattern as the reference (HPA tissue IHC). |
| Staining appears mainly nuclear. | A nuclear-dominant pattern conflicts with HPA's cytoplasmic tissue profile and mainly cytosolic ICC-IF finding (HPA tissue IHC; HPA subcellular). Its cause cannot be assigned from the pattern alone. | Compare with the no-primary control, review counterstain and detection, and repeat interpretation in a reported positive cell type (general IHC practice; HPA tissue IHC). |
| Adipocytes or other HPA-negative cell types look positive. | Cross-reactivity or endogenous detection activity is possible (general IHC practice); HPA reports adipocytes, prostate glandular cells and germinal-center cells as Not detected (HPA tissue IHC). | Check a no-primary control and the relevant endogenous-activity block for the chromogenic method, then reassess the specific cell type (general IHC practice). |
| The whole section has diffuse brown background. | Nonspecific detection or excessive chromogen development can obscure cell boundaries (general IHC practice). Diffuse color does not match HPA's cell-associated cytoplasmic description (HPA tissue IHC). | Review blocking, washes and development time alongside a no-primary control; score only interpretable cellular staining (general IHC practice). |
| An IF/ICC image shows membrane-associated signal. | Additional plasma-membrane localization is reported in ICC-IF, alongside a mainly cytosolic signal (HPA subcellular); the tissue IHC profile remains cytoplasmic (HPA tissue IHC). | Assess the IF/ICC observation within that application and use the cytoplasmic, cell-type-specific pattern to interpret paraffin IHC (HPA subcellular; HPA tissue IHC). |
Experiment evidence
IHC & IF images showing SOCS3 staining
PA1707 · IHCIHC analysis of SOCS3 using anti-SOCS3 antibody (PA1707). SOCS3 was detected in paraffin-embedded section of human tonsil tissues. Heat medi
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000184557-SOCS3/tissue/cerebral+cortex#imid_3707824
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000184557-SOCS3/tissue/colon#imid_3707734
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000184557-SOCS3/tissue/liver#imid_3707743
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000184557-SOCS3/tissue/kidney#imid_3707736
HPA · ICC-IF ASC52teloHuman Protein Atlas immunofluorescence, ASC52telo, antibody HPA068569; green = SOCS3, blue = nucleus, red = microtubules.
HPA · ICC-IF ASC52teloHuman Protein Atlas immunofluorescence, ASC52telo, antibody HPA068569; green = SOCS3, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SOCS3 IHC & IF
🧪Run fallopian tube first; its non-ciliated cells should stain for SOCS3 (HPA: High in non-ciliated cells). Use prostate glandular cells as the negative tissue (HPA: Not detected); on the positive slide, assess cells outside the non-ciliated compartment as potential internal negatives, without assuming they are SOCS3-negative (HPA: staining specified for non-ciliated cells only).
Positive control tissue: Fallopian tube (Non-ciliated cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SOCS3 in ASC52telo, BJ [Human fibroblast], U2OS, with annotated localisation: Cytosol (approved) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control, a concentration-matched nonimmune rabbit IgG isotype control, and a validated SOCS3-knockout biological negative (caption: rabbit primary; standard IHC practice). For DAB detection, check endogenous peroxidase and endogenous biotin background in the fallopian tube section (caption: biotinylated secondary, streptavidin–biotin complex, and DAB; standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected PA1707 caption does not state the fixative (caption: fixative not stated). The demonstrated paraffin-section method uses citrate retrieval at pH 6 for 20 minutes; whether SOCS3 staining depends on that retrieval is unreported (caption: retrieval conditions). The supplied evidence does not establish that frozen sections or IF are easier; for the fallopian tube IHC run, evaluate endogenous peroxidase and biotin background (HPA: High in fallopian tube non-ciliated cells; caption: biotin–DAB detection).
HPA tissue IHC evidence for SOCS3
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Fallopian tube | Non-ciliated cells | High | Protein (IHC) | HPA → |
| Gallbladder | Glandular cells | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Medium | Protein (IHC) | HPA → |
| Bronchus | Basal cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Lymph node | Germinal center cells | Not detected | Protein (IHC) | HPA → |
| Prostate | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Smooth muscle | Smooth muscle cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SOCS3 IHC Tips
These questions address SOCS3 staining in paraffin sections by chromogenic IHC, with one entry on translating the readout to IF.
What retrieval conditions should I try first when SOCS3 staining is weak?
Start with heat-mediated antigen retrieval in citrate buffer at pH 6 for 20 minutes (datasheet PA1707). The documented paraffin-section workflow then uses 10% goat serum, 1 μg/ml primary antibody overnight at 4°C, and DAB detection (datasheet PA1707). If staining remains weak, compare a modestly adjusted heating time on matched sections while keeping buffer, antibody concentration, and detection constant (standard IHC practice). Include a no-primary control and examine tissue preservation alongside signal, because excessive retrieval can damage morphology or increase nonspecific staining (standard IHC practice). The caption does not identify a fixative, so retrieval performance after a particular fixation method remains unestablished (datasheet PA1707).
How should I troubleshoot variable SOCS3 staining across differently fixed sections?
Target-specific SOCS3 sensitivity to fixation is unknown from the supplied evidence; the PA1707 tissue caption identifies paraffin sections but does not state their fixative (datasheet PA1707). Record each specimen’s fixative and fixation duration, and compare sections processed and stained together before assigning differences to SOCS3 expression (standard IHC practice). Begin with citrate retrieval at pH 6 for 20 minutes when using the documented antibody workflow (datasheet PA1707). Check morphology, reagent controls, and staining in comparable cell populations; poor preservation can make an apparent loss of signal hard to interpret (standard IHC practice). Do not use tissue expression patterns to infer fixation tolerance.
Should SOCS3 staining be cytoplasmic, membranous, or nuclear in tissue sections?
Expect predominantly cytoplasmic staining in most tissues (HPA tissue IHC: cytoplasmic expression); cell imaging places SOCS3 mainly in the cytosol with an additional plasma-membrane location (HPA subcellular: approved). Interpret membrane-associated staining cautiously because the record lists no transmembrane segment, while SOCS3 can bind activated signaling receptors (UniProt O14543: topology and function). Compare compartment patterns in the same cell type across matched sections and inspect the no-primary control before calling a weak rim specific (standard IHC practice). A nuclear-only pattern needs further validation against an independent antibody or orthogonal assay; the supplied localisation evidence does not establish the nucleus as the principal compartment (HPA subcellular).
Could an isoform or hidden epitope explain discordant SOCS3 IHC results?
The supplied record lists a single 225-aa SOCS3 chain and 0 annotated isoforms, so an isoform explanation lacks support here (UniProt O14543: processing and isoforms). Its SH2 domain spans residues 46–142 and its SOCS box spans 177–224, but the antibody epitope is not supplied (UniProt O14543: domains; datasheet PA1707). Do not attribute a staining difference to either domain without epitope-mapping evidence (standard IHC interpretation). Compare adjacent sections under the documented citrate pH 6 retrieval condition and check reagent controls first (datasheet PA1707; standard IHC practice). If disagreement persists, test an independently characterised antibody with a known, distinct epitope (standard IHC practice).
How can I assess SOCS3 by IF alongside a cell-type marker?
For IF, pair SOCS3 with a validated marker for the cell population being examined and assess both signals within individual cells (standard IF practice). Choose spectrally separated fluorophores and place the dimmer signal in a channel with low measured tissue autofluorescence; include single-label and no-primary controls (standard IF practice). Permeabilise sufficiently to expose a cytosolic epitope, because cytosol is the approved main location, while testing a milder condition if assessing membrane-associated signal (HPA subcellular; standard IF practice). The antibody’s exact epitope is unspecified, so its accessibility under either condition requires experimental verification (datasheet PA1707). Use the dedicated IF/ICC guide for its validated workflow.
How do I distinguish diffuse SOCS3 signal from chromogenic background?
Compare stained sections with a no-primary control and inspect whether DAB deposits follow intact cell boundaries or instead collect at folds, edges, and damaged areas (standard IHC practice). Include a peroxidase-blocking step before chromogenic detection and verify that secondary-antibody and avidin-biotin reagents do not produce signal without primary antibody (standard IHC practice). The documented PA1707 example used biotinylated goat anti-rabbit secondary, streptavidin-biotin complex, and DAB after 10% goat-serum blocking (datasheet PA1707). Reduce nonspecific staining by optimising antibody concentration and washes on matched sections, starting from the documented 1 μg/ml primary concentration (datasheet PA1707; standard IHC practice). Judge residual cytoplasmic staining against tissue and cell-type expectations (HPA tissue IHC).
How should I score SOCS3 IHC across specimens with different cell mixtures? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and scoring region before analysis, then report the percentage of positive cells and an intensity-weighted H-score using the same thresholds across specimens (standard IHC practice). Alternatively, report positive-cell density per mm² when cell counts per area answer the study question (standard IHC practice). Normalise each measure to the relevant viable cell population or sampled tissue area, and exclude folds and necrotic regions by a prespecified rule (standard IHC practice). Separate cytoplasmic from membrane-associated scores if both patterns occur, because cytosol is the approved main location and plasma membrane an additional location (HPA subcellular). Record batch and control performance alongside the scores (standard IHC practice).
What would make an apparent SOCS3-positive cell convincing rather than artefactual?
A convincing call combines staining in an intact cell, the expected predominantly cytoplasmic pattern, and a clean no-primary control (HPA tissue IHC; standard IHC practice). The HPA reports high staining in fallopian-tube non-ciliated cells and gallbladder glandular cells, but no detection in lymph-node germinal-center cells; compare equivalent cell populations rather than whole tissues (HPA tissue IHC). Treat edge deposits, necrotic material, and staining that survives omission of primary antibody as possible artefacts (standard IHC practice). Check endogenous peroxidase blocking when DAB signal appears broadly independent of cell identity (standard IHC practice). HPA tissue-IHC reliability is marked Approved with external verification pending, so corroborate consequential findings independently (HPA tissue IHC).
Boster reagents
Best SOCS3 / Suppressor of cytokine signaling 3 IHC Antibodies
PA1707 is listed for human and mouse IHC (catalog: applications/reactivity), with an IHC image from paraffin-embedded human tonsil (PA1707 image caption). No IF/ICC data are listed (catalog: applications/images).
Real IHC data
Anti-SOCS3 Antibody ®
Cat # PA1707
PA1707 is listed for IHC in human and mouse (catalog: applications/reactivity). Its own image documents staining of a paraffin-embedded human tonsil section after citrate retrieval, with DAB detection (PA1707 image caption).
Which to pick: For paraffin-section IHC, choose PA1707 at 0.5–1 μg/ml (datasheet: IHC dilution); its image documents this sample preparation, but does not report the fixative (PA1707 image caption). No SKU in the payload is listed for IF/ICC (catalog: applications/images). For human or mouse IHC, PA1707 is the listed option (catalog: reactivity); its host is rabbit, and its clonality is unreported (catalog: host/clone).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O14543 (SOCS3_HUMAN, Suppressor of cytokine signaling 3).
- Human Protein Atlas. SOCS3 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. SOCS3 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to the plasma membrane..
- Human Protein Atlas. SOCS3 antibody validation summary (2 antibodies).
- Suppressor of cytokine signalling protein SOCS3 expression is increased at sites of acute and chronic inflammation. Journal of molecular histology 2011 — PMC3070874.
- Effect of Total Flavonoids of Oxytropis falcata Bunge on the Expression of p-JAK1-and p-STAT1-Related Proteins in Idiopathic Pulmonary Fibrosis. Evidence-based complementary and alternative medicine : eCAM 2020 — PMC7474768.
- Loss of expression and function of SOCS3 is an early event in HNSCC: altered subcellular localization as a possible mechanism involved in proliferation, migration and invasion. PloS one 2012 — PMC3445460.
- Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients. Journal of Cancer 2020 — PMC7391185.
- PubMed PMID:9266833 — UniProt-cited evidence.
- PubMed PMID:9344848 — UniProt-cited evidence.
- PubMed PMID:11071852 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SOCS3 (Suppressor of cytokine signaling 3). Expected localisation Cytoplasmic staining in most tissues (HPA tissue IHC). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet PA1707). Validated IHC antibody: PA1707 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Fallopian tube (Non-ciliated cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human tonsil tissues; fixative not specified (datasheet PA1707); 2. Fixation: Image fixative and duration unreported (datasheet PA1707); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet PA1707); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet PA1707); 8. Primary antibody: Rabbit anti-SOCS3, 0.5-1μg/ml (datasheet PA1707); 9. Primary incubation: Overnight at 4 °C (datasheet PA1707). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: Adipocytes are undetected despite adipose RNA enrichment (HPA tissue IHC; HPA RNA); Isoform / epitope: No annotated isoforms; one chain, residues 1–225 (UniProt); Regulation: Cytokine inducible (UniProt). Evidence: UniProt O14543, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the cytosol. In addition localized to the plasma…, Datasheet PA1707, PMC3070874, PMC7474768. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SOCS3/immunohistochemistry-ihc-guide.